Starbucks ends employee coverage for these medicines amid rising US health costs
Starbucks is ending health insurance coverage for GLP-1 weight-loss drugs for its employees, citing rising healthcare costs. The company joins other major employers in recalibrating benefits as claims for these medications continue to surge.
Why it matters
The decision highlights the growing financial pressure on corporate health plans due to the widespread adoption of expensive weight-loss treatments.
Starbucks has announced that it will stop covering the GLP-1 medications prescribed for weight loss under its employee health plans starting October. According to a report by Business Insider, the Seattle-based coffee chain has confirmed that while the drugs may still be covered for other conditions such as diabetes, they will no longer be included for weight-loss purposes. Starbucks provides health benefits to full- and part-time employees working at least 20 hours a week.Reason behind Starbucks pulling back coverage for weight-loss drugsThis move by Starbucks reflects a broader trend among US employers recalibrating benefits as spending on GLP-1 drugs surges. Originally developed for diabetes, these medicines have become popular for obesity treatment. According to the International Foundation of Employee Benefit Plans, GLP-1 drugs accounted for 11.4% of corporate employers’ total annual claims in 2025, up from 6.9% in 2023.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in